Changes in cytokine complexes in children with autoimmune diseases with different effectiveness of their biological therapy

Introduction. Cytokines (CC) play an important pathogenetic role in the development of autoimmune diseases. Over the past decade, there  has appeared a huge number of biological drugs that target certain cytokines. The main problem remains the choice of a suitable biological drug, as up to 40% of patients do not respond to treatment or become resistant to it.

Aim: to identify informative cytokine complexes in children with psoriasis, MS, and IBD with different efficacy of biological therapy.

Materials and methods. Two hundred eighty eight children with autoimmune diseases were examined against the background of supportive biological therapy. Patients were divided into groups of exacerbation and remission depending on the lesion area index PASI for psoriasis (PS), clinical activity indices PUCAI for ulcerative colitis (UC), PCDIA for Crohn’s disease (CD), by the pre­sence of foci of demyelination on MRI for patients with multiple sclerosis (MS). All patients underwent a study of 25 cytokines in serum samples using multiplex analysis (X-MAP technology).

Results. In PS, MS, UC, and CD patients, an increase in pathogenetically significant cytokine profiles associated with cells (c) and functions (f) of M1 cells, Th1, Th2, Th17 was revealed in the exacerbation of diseases relative to the groups in remission. There was a significant decrease in the levels of cytokines and cytokine complexes in patients with MS relative to patients with PS, UC and CD, with the exception of cTh1. Threshold values of the level of cytokine complexes above which the development of an exacerbation of the disease can be expected were obtained: for PS — 1431.1 pg/ml (fTh22 — IL13 + Il22), for PC — 33.1 pg/ml (cTh1 — IFN-γ + IL12p70 + TNF-β + IL2), UC — 20.9 pg/ml (M1 — IL-1 + IL-6 + TNF-α), CD — 1986 pg/ml (fIL12 — IL12 + IL23 + IL27).

Conclusion. To assess the effectiveness of biological therapy and to predict the condition of patients, it is possible to evaluate specific cytokine complexes for a specific pathology.

Contribution:
Radygina T.V., Petrichuk S.V. — research concept and design of the study;
Radygina T.V., Petrichuk S.V., Kuptsova D.G., Kurbatova O.V., Potapov A.S., Murashkin N.N., Bursagova B.I., Abdullaeva L.M., Freydlin E.V. — collection and processing of material;
Radygina T.V. — text writing;
Radygina T.V., Petrichuk S.V., Kuptsova D.G., Potapov A.S., Kurbatova O.V., Abdullaeva L.M., Semikina E.L., Fisenko A.P. — editing.
All co-authors — approval of the final version of the article, responsibility for the integrity of all parts of the article.

Acknowledgment.  The study was conducted within the framework of the state assignment of the Ministry of Health of the Russian Federation, No. AAAAA-A19-119013090093-2.

Conflict of interest. The authors declare no conflict of interest.

Received: November 14, 2023
Accepted: November 28, 2023
Published: December 27, 2023

1. Jung S.M., Kim W.U. Targeted immunotherapy for autoimmune disease. Immune Netw. 2022; 22(1): e9. https://doi.org/10.4110/in.2022.22.e9

2. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 1957; 147(927): 258–67. https://doi.org/10.1098/rspb.1957.0048

3. van de Veerdonk F.L., Stoeckman A.K., Wu G., Boeckermann A.N., Azam T., Netea M.G., et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc. Natl Acad. Sci. USA. 2012; 109(8): 3001–5. https://doi.org/10.1073/pnas.1121534109

4. Turner M.D., Nedjai B., Hurst T., Pennington D.J. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim. Biophys. Acta. 2014; 1843(11): 2563–82. https://doi.org/10.1016/j.bbamcr.2014.05.014

5. Chetaille Nézondet A.L., Poubelle P.E., Pelletier M. The evaluation of cytokines to help establish diagnosis and guide treatment of autoinflammatory and autoimmune diseases. J. Leukoc. Biol. 2020; 108(2): 647–57. https://doi.org/10.1002/JLB.5MR0120-218RRR

6. Conrad N., Misra S., Verbakel J.Y., Verbeke G., Molenberghs G., Taylor P.N., et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023; 401(10391): 1878–90. https://doi.org/10.1016/ S0140-6736(23)00457-9

7. Ott A., Tutdibi E., Goedicke-Fritz S., Schöpe J., Zemlin M., Nourkami-Tutdibi N. Serum cytokines MCP-1 and GCS-F as potential biomarkers in pediatric inflammatory bowel disease. PLoS One. 2023; 18(11): e0288147. https://doi.org/10.1371/journal.pone.0288147

8. Kuptsova D.G., Petrichuk S.V., Murashkin N.N., Radygina T.V., Kurbatova O.V. Contents of CD4+ and CD8+ memory cell subpopulations and circulating cytokine levels in psoriasis in children. Vestnik Ural’skoy meditsinskoy akademicheskoy nauki. 2022; 19(3): 163–72. https://doi.org/10.22138/2500-0918-2022-19-3-163-172 https://elibrary.ru/rlzjak (in Russian)

9. Miroshkina L.V., Petrichuk S.V., Tsimbalova E.G., Potapov A.S., Venediktova M.M., Toptygina A.P., et al. Cytokine profile as predictor of infliximab therapy effectiveness in children with inflammatory bowel diseases. Voprosy diagnostiki v pediatrii. 2013; 5(4): 33–8. https://elibrary.ru/reiglx (in Russian)

10. Magro F., Gionchetti P., Eliakim R., Ardizzone S., Armuzzi A., Barreiro-de Acosta M., et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J. Crohns. Colitis. 2017; 11(6): 649–70. https://doi.org/10.1093/ecco-jcc/jjx008

11. Kaser A., Adolph T.E., Blumberg R.S. The unfolded protein response and gastrointestinal disease. Semin. Immunopathol. 2013; 35(3): 307–19. https://doi.org/10.1007/s00281-013-0377-5

12. Pavlidis S., Monast C., Loza M.J., Branigan P., Chung K.F., Adcock I.M., et al. I_MDS: an inflammatory bowel disease molecular activity score to classify patients with differing disease-driving pathways and therapeutic response to anti-TNF treatment. PLoS Comput. Biol. 2019; 15(4): e1006951. https://doi.org/10.1371/journal.pcbi.1006951

13. Menegatti S., Bianchi E., Rogge L. Anti-TNF therapy in spondyloarthritis and related diseases, impact on the immune system and prediction of treatment responses. Front. Immunol. 2019; 19(10): 382. https://doi.org/10.3389/fimmu.2019.00382

14. Privitera G., Pugliese D., Rapaccini G., Gasbarrini A., Armuzzi A., Guidi L. Predictors and early markers of response to biological therapies in inflammatory bowel diseases. J. Clin. Med. 2021; 10(4): 853. https://doi.org/10.3390/jcm10040853

15. Wang Q., Yan D., Zheng S., Li M., Li J., Fu X., et al. Cytokine profiles and the relationship of disease severity in patients with psoriasis. Indian J. Dermatol. 2022; 67(2): 204. https://doi.org/10.4103/ijd.ijd_79_22

16. Kobayashi T., Siegmund B., Le B.C., Wei SC., Ferrante M., Shen B., et al. Ulcerative colitis. Nat. Rev. Dis. Primers. 2020; 6: 74. https://doi.org/10.1038/s41572-020-0205-x

17. Bai Z., Chen D., Wang L., Zhao Y., Liu T., Yu Y., et al. Cerebrospinal fluid and blood cytokines as biomarkers for multiple sclerosis: a systematic review and meta-analysis of 226 studies with 13,526 multiple sclerosis patients. Front. Neurosci. 2019; 13: 1026. https://doi.org/10.3389/fnins.2019.01026

18. Maes M., Carvalho A.F. The compensatory immune-regulatory reflex system (CIRS) in depression and bipolar disorder. Mol. Neurobiol. 2018; 55(12): 8885–903. https://doi.org/10.1007/s12035-018-1016-x

19. Cala C.M., Moseley C.E., Steele C., Dowdy S.M. T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis. J. Neuroimmunol. 2016; 297: 1–8. https://doi.org/10.1016/j.jneuroim.2016.04.015

20. Zhang J.M., An J. Cytokines, inflammation, and pain. Int. Anesthesiol. Clin. 2007; 45(2): 27–37. https://doi.org/10.1097/AIA.0b013e318034194e

21. Chen Z., Bozec A., Ramming A., Schettet G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat. Rev. Rheumatol. 2019; 15(1): 9–17. https://doi.org/10.1038/s41584-018-0109-2

22. Cataldi C., Mari N.L., Lozovoy M.A.B., Martins L.M.M., Reiche E.M.V., Maes M., et al. Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors. Inflamm. Res. 2019; 68(7): 557–67. https://doi.org/10.1007/s00011-019-01238-8